LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

Accueil・Liste d'Actions・Editas Medicine Inc

Editas Medicine Inc

Ouvert

SecteurSoins de santé

2.89 -2.36

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.87

Max

2.98

Chiffres clés
By Trading Economics
Revenu	-19M -25M
Ventes	-22M 2.8M
BPA	-0.26
Marge bénéficiaire	-882.444
Employés	87
EBITDA	-19M -25M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+96.93% upside

Dividendes
By Dow Jones
Prochains Résultats	10 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	5.9M 300M
Ouverture précédente	5.25
Clôture précédente	2.89

Sentiment de l'Actualité

By Acuity

92%

7 / 346 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

1.33 / 1.54 Support & Résistance

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 mai 2026, 22:50 UTC

Résultats

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mai 2026, 22:49 UTC

Résultats

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mai 2026, 22:32 UTC

Résultats

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mai 2026, 22:57 UTC

Market Talk

Résultats

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mai 2026, 22:26 UTC

Résultats

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mai 2026, 22:25 UTC

Résultats

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mai 2026, 22:25 UTC

Résultats

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mai 2026, 22:24 UTC

Résultats

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mai 2026, 22:23 UTC

Résultats

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mai 2026, 22:23 UTC

Résultats

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mai 2026, 22:19 UTC

Résultats

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mai 2026, 22:14 UTC

Résultats

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mai 2026, 22:14 UTC

Résultats

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mai 2026, 22:13 UTC

Résultats

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Résultats

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Résultats

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mai 2026, 22:11 UTC

Résultats

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mai 2026, 22:11 UTC

Résultats

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mai 2026, 22:10 UTC

Résultats

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mai 2026, 22:09 UTC

Résultats

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mai 2026, 22:09 UTC

Résultats

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mai 2026, 22:08 UTC

Résultats

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mai 2026, 22:07 UTC

Résultats

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mai 2026, 22:06 UTC

Résultats

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mai 2026, 22:06 UTC

Résultats

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mai 2026, 22:05 UTC

Résultats

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

96.93% hausse

Prévisions sur 12 Mois

Moyen 5.77 USD 96.93%

Haut 15 USD

Bas 3 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

Achat

Maintien

Vente

Basé sur 10 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.33 / 1.54Support & Résistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentiment

By Acuity

7 / 346Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.